Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities
December 13 2024 - 1:00AM
UK Regulatory
Roche receives CE Mark for new and updated molecular cobas
6800/8800 systems, enhancing laboratory efficiency and testing
capabilities
- The new cobas 6800/8800
systems 2.0 enhances throughput, run flexibility, enables sample
prioritisation and is available as an upgrade to existing systems
in healthcare settings around the world.
-
Laboratories can now perform a wider range of tests on a
single solution, simplifying laboratory logistics and helping to
optimise the use of resources.
Basel, 13 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY)
announced today the CE certification of the new cobas® 6800/8800
systems 2.0. The update significantly enhances the efficiency of
laboratories by optimising resources, reducing downtime,
consolidating test menus, and increasing throughput. These
improvements ultimately promise a more streamlined diagnostics
experience for healthcare professionals and their patients.
“This update marks another significant milestone for Roche,”
said Matt Sause, CEO of Roche Diagnostics. “With our history of
leading innovation in automated molecular testing, it represents
another competitive leap forward in our efforts to advance PCR
technology by combining unprecedented throughput together with the
flexibility that laboratories require to deliver for physicians and
patients.”
Unified User Experience and Innovative
Technologies
The majority of the cobas test menu is available with the release
of the update, including the powerful new Temperature-Activated
Generation of Signal (TAGS) technology. TAGS technology enables up
to 15 targets to be detected simultaneously in a single patient
sample on the high throughput molecular diagnostic analysers cobas
5800, 6800 and 8800 systems.
The cobas 6800/8800 systems are designed to address challenges
faced by mid-to-high volume molecular testing laboratories.
Bringing the latest innovations to transform the testing
experience, the systems offer intelligent workflows, unrivalled
throughput, proven performance, established reliability, and
outstanding flexibility.
With this upgrade, the cobas family of solutions provides a
unified user experience, incorporating significant innovations from
the newest addition to the family, the cobas 5800 system.
The U.S. 510(k) clearance from the FDA will follow with
submission planned for 2025.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first
industrial manufacturers of branded medicines, Roche has grown into
the world’s largest biotechnology company and the global leader in
in-vitro diagnostics. The company pursues scientific excellence to
discover and develop medicines and diagnostics for improving and
saving the lives of people around the world. We are a pioneer in
personalised healthcare and want to further transform how
healthcare is delivered to have an even greater impact. To provide
the best care for each person we partner with many stakeholders and
combine our strengths in Diagnostics and Pharma with data insights
from the clinical practice.
For over 125 years, sustainability has been an integral part of
Roche’s business. As a science-driven company, our greatest
contribution to society is developing innovative medicines and
diagnostics that help people live healthier lives. Roche is
committed to the Science Based Targets initiative and the
Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the
Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees,
PhD
Phone: +41 79 407 72 58 |
Sileia
Urech
Phone: +41 79 935 81 48
|
Nathalie
Altermatt
Phone: +41 79 771 05 25 |
Lorena
Corfas
Phone: +41 79 568 24 95
|
Simon
Goldsborough
Phone: +44 797 32 72 915 |
Karsten
Kleine
Phone: +41 79 461 86 83
|
Nina
Mählitz
Phone: +41 79 327 54 74 |
Kirti
Pandey
Phone: +49 172 6367262
|
Yvette
Petillon
Phone: +41 79 961 92 50 |
Dr Rebekka
Schnell
Phone: +41 79 205 27 03 |
- 13122024_MR_CE Mark for cobas6800_8800_en
Roche (LSE:0QQ6)
Historical Stock Chart
From Nov 2024 to Dec 2024
Roche (LSE:0QQ6)
Historical Stock Chart
From Dec 2023 to Dec 2024